Bank of New York Mellon Corp - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 414 filers reported holding CRISPR THERAPEUTICS AG in Q4 2020. The put-call ratio across all filers is 1.10 and the average weighting 0.3%.

Quarter-by-quarter ownership
Bank of New York Mellon Corp ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$4,784,807
-21.1%
105,415
-2.5%
0.00%0.0%
Q2 2023$6,067,876
+23.2%
108,085
-0.7%
0.00%0.0%
Q1 2023$4,923,588
+11.2%
108,857
-0.0%
0.00%0.0%
Q4 2022$4,427,057
-42.8%
108,907
-8.1%
0.00%
-50.0%
Q3 2022$7,741,000
+25.2%
118,444
+16.4%
0.00%
+100.0%
Q2 2022$6,185,000
+8.2%
101,775
+11.8%
0.00%0.0%
Q1 2022$5,716,000
+16.6%
91,062
+40.7%
0.00%0.0%
Q4 2021$4,903,000
-29.4%
64,704
+4.2%
0.00%0.0%
Q3 2021$6,948,000
-30.0%
62,068
+1.2%
0.00%
-50.0%
Q2 2021$9,925,000
+81.3%
61,306
+36.4%
0.00%
+100.0%
Q1 2021$5,475,000
-10.3%
44,937
+12.8%
0.00%0.0%
Q4 2020$6,101,000
-69.6%
39,847
-83.4%
0.00%
-80.0%
Q3 2020$20,066,000
+22.0%
239,903
+7.2%
0.01%
+25.0%
Q2 2020$16,445,000
+85.1%
223,785
+6.9%
0.00%
+33.3%
Q1 2020$8,883,000
+215.9%
209,431
+353.6%
0.00%
+200.0%
Q4 2019$2,812,000
+74.1%
46,167
+17.1%
0.00%
Q3 2019$1,615,000
+3.6%
39,431
+19.2%
0.00%
Q2 2019$1,559,000
+185.5%
33,091
+116.5%
0.00%
Q1 2019$546,000
+10.8%
15,281
-11.4%
0.00%
Q4 2018$493,000
-67.9%
17,251
-50.2%
0.00%
Q3 2018$1,535,000
-16.0%
34,618
+11.3%
0.00%
Q2 2018$1,827,000
+83.6%
31,104
+42.8%
0.00%
Q1 2018$995,000
+245.5%
21,778
+35.0%
0.00%
Q3 2017$288,00016,1320.00%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q4 2020
NameSharesValueWeighting ↓
Versant Venture Management, LLC 498,558$32,581,00055.55%
NEA Management Company, LLC 1,590,002$103,907,0005.19%
ARK Investment Management 8,237,122$538,296,0003.75%
Nikko Asset Management Americas, Inc. 4,262,736$277,078,0003.54%
CLOUGH CAPITAL PARTNERS L P 414,767$27,105,0002.89%
Integral Health Asset Management, LLC 220,000$14,377,0002.79%
PLUSTICK MANAGEMENT LLC 50,000$3,268,0002.48%
HC Advisors, LLC 53,944$3,525,0002.43%
Green Alpha Advisors, LLC 27,466$1,795,0001.52%
EFG Asset Management (North America) Corp. 84,356$5,516,0001.28%
View complete list of CRISPR THERAPEUTICS AG shareholders